Plexision105 Jan, 2021Health
Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision�s CLIA-certified, central laboratory in Pittsburgh.
Vsbetappinnet
Pg88
Dh88tech1
Kim88register
Adam Duong
Journey Of Himalayas
Chaya Mina
Sunwin109 Net
NhĂ´m KĂnh Hdpwindow
Nhà Cái Uy88